卡莱宾A向HIF-1α/NF-κB通路,以抑制结直肠癌细胞迁移
Aranka Brockmueller1, Sosmitha Girisa2, Mahzad Motallebi3
1Chair of Vegetative Anatomy, Institute of Anatomy, Faculty of Medicine, Ludwig-Maximilians-University Munich, Munich, Germany.
Frontiers in pharmacology
|August 16, 2023
概括
卡莱宾A (CA) 通过向缺氧诱导因子-1α (HIF-1α) 和NF-κB. 抑制结肠直肠癌 (CRC) 细胞迁移和增殖. 这种化合物通过调节瘤恶性瘤的关键因素,显示出癌症治疗的前景.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 缺氧诱导因子-1α (HIF-1α) 是一个关键的转录因子,影响瘤细胞代谢,生存,增殖,血管生成和转移.
- 来自黄的Calebin A (CA) 通过NF-κB通路调节表现出抗癌特性.
- 在结直肠癌 (CRC) 细胞迁移中CA对HIF-1α的影响仍然未被探索.
研究的目的:
- 调查Calebin A (CA) 对瘤微环境 (TME) 诱导的结肠直肠癌 (CRC) 细胞炎症,迁移和恶性瘤的疗效.
- 探索HIF-1α在CA对CRC细胞的抗癌作用中的作用.
- 阐明HIF-1α和NF-κB在CRC进展中的相互作用以及CA对这种相互作用的调制.
主要方法:
- 人类CRC细胞 (HCT-116) 在3D酸盐中培养,并与TME组件 (纤维细胞/T淋巴细胞) 共同培养.
- 用CA或HIF-1α抑制剂对细胞进行治疗,以评估对增殖,迁移和亡的影响.
- 西方斑点分析,殖民地形成试验,托卢伊丁蓝色染色和电子显微镜被用来评估分子变化和细胞行为.
主要成果:
- CA显著抑制了TME促进的HCT-116细胞的增殖和迁移,与HIF-1α抑制相当.
- CA抑制了HIF-1α表达和下游转移性生物标志物 (NF-κB,β1-整蛋白,VEGF),同时促进了细胞灭绝 (caspase-3).
- TME诱导了HIF-1α和NF-κB之间的协同相互作用,CA有效地使其沉默,从而抑制CRC细胞恶性病变和迁移.
结论:
- 卡莱宾A (CA) 通过部分抑制HIF-1α和NF-κB信号通路,在结直肠癌 (CRC) 中表现出显著的抗癌活性.
- CA调节HIF-1α/NF-κB轴的能力为CRC提供了一个新的治疗策略.
- 这些发现突出了CA作为癌症治疗的潜在药物,向瘤恶性和转移的关键机制.
相关概念视频
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Co-activators and Co-repressors
7.4K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.4K
MAPK Signaling Cascades
5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K


